skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Stereotactic Radiofrequency Ablation for Metastatic Melanoma to the Liver

Abstract

PurposeTo evaluate the outcome of patients with melanoma liver metastasis treated with stereotactic radiofrequency ablation (SRFA).Material and MethodFollowing IRB approval, a retrospective evaluation of the treatment of 20 patients with 75 melanoma liver metastases was performed.ResultsA median number of 2 lesions (range 1–14) per patient with a median size of 1.7 cm (range 0.5–14.5 cm) were treated. 67 lesions were <3 cm (89.3 %) and 8 lesions were >3 cm (10.7 %). Per patient a median of 1 ablation session was performed (range: 1–4) totaling 34 sessions. There were no procedure-related deaths and all major complications (n = 3) could be easily treated by pleural drainages. The primary and secondary success rates were 89.3 and 93.3 %, respectively. The overall local recurrence rate was 13.3 %. Four of ten local recurrences were re-treated successfully by SRFA. During follow-up, 9/20 patients developed extrahepatic metastatic disease and 10/20 had liver recurrence at any location. The median OS from the date of SRFA was 19.3 months, with an OS of 64, 41, and 17 % at 1, 3, and 5 years, with no significant difference for patients with cutaneous and ocular melanoma. The median DFS after SRFA for all 20 patients was 9.5 months, with 37, 9, and 0 % at 1, 3, and 5 years.ConclusionsDue to the highmore » local curative potential and the promising long-term survival rates associated with minimal morbidity and mortality, radiofrequency ablation seems to be an attractive alternative to resection in patients with melanoma liver metastases.« less

Authors:
;  [1];  [2]; ;  [1];  [2]
  1. Medical University Innsbruck, Department of Radiology, Section of Interventional Oncology - Microinvasive Therapy (SIP) (Austria)
  2. Medical University Innsbruck, Department of Dermatology (Austria)
Publication Date:
OSTI Identifier:
22645485
Resource Type:
Journal Article
Resource Relation:
Journal Name: Cardiovascular and Interventional Radiology; Journal Volume: 39; Journal Issue: 8; Other Information: Copyright (c) 2016 Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE); http://www.springer-ny.com; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; ABLATION; DEATH; DISEASE INCIDENCE; EVALUATION; LIVER; MELANOMAS; METASTASES; MORTALITY; PATIENTS; RADIOWAVE RADIATION

Citation Formats

Bale, Reto, E-mail: reto.bale@i-med.ac.at, Schullian, Peter, Schmuth, Matthias, Widmann, Gerlig, Jaschke, Werner, and Weinlich, Georg. Stereotactic Radiofrequency Ablation for Metastatic Melanoma to the Liver. United States: N. p., 2016. Web. doi:10.1007/S00270-016-1336-Z.
Bale, Reto, E-mail: reto.bale@i-med.ac.at, Schullian, Peter, Schmuth, Matthias, Widmann, Gerlig, Jaschke, Werner, & Weinlich, Georg. Stereotactic Radiofrequency Ablation for Metastatic Melanoma to the Liver. United States. doi:10.1007/S00270-016-1336-Z.
Bale, Reto, E-mail: reto.bale@i-med.ac.at, Schullian, Peter, Schmuth, Matthias, Widmann, Gerlig, Jaschke, Werner, and Weinlich, Georg. Mon . "Stereotactic Radiofrequency Ablation for Metastatic Melanoma to the Liver". United States. doi:10.1007/S00270-016-1336-Z.
@article{osti_22645485,
title = {Stereotactic Radiofrequency Ablation for Metastatic Melanoma to the Liver},
author = {Bale, Reto, E-mail: reto.bale@i-med.ac.at and Schullian, Peter and Schmuth, Matthias and Widmann, Gerlig and Jaschke, Werner and Weinlich, Georg},
abstractNote = {PurposeTo evaluate the outcome of patients with melanoma liver metastasis treated with stereotactic radiofrequency ablation (SRFA).Material and MethodFollowing IRB approval, a retrospective evaluation of the treatment of 20 patients with 75 melanoma liver metastases was performed.ResultsA median number of 2 lesions (range 1–14) per patient with a median size of 1.7 cm (range 0.5–14.5 cm) were treated. 67 lesions were <3 cm (89.3 %) and 8 lesions were >3 cm (10.7 %). Per patient a median of 1 ablation session was performed (range: 1–4) totaling 34 sessions. There were no procedure-related deaths and all major complications (n = 3) could be easily treated by pleural drainages. The primary and secondary success rates were 89.3 and 93.3 %, respectively. The overall local recurrence rate was 13.3 %. Four of ten local recurrences were re-treated successfully by SRFA. During follow-up, 9/20 patients developed extrahepatic metastatic disease and 10/20 had liver recurrence at any location. The median OS from the date of SRFA was 19.3 months, with an OS of 64, 41, and 17 % at 1, 3, and 5 years, with no significant difference for patients with cutaneous and ocular melanoma. The median DFS after SRFA for all 20 patients was 9.5 months, with 37, 9, and 0 % at 1, 3, and 5 years.ConclusionsDue to the high local curative potential and the promising long-term survival rates associated with minimal morbidity and mortality, radiofrequency ablation seems to be an attractive alternative to resection in patients with melanoma liver metastases.},
doi = {10.1007/S00270-016-1336-Z},
journal = {Cardiovascular and Interventional Radiology},
number = 8,
volume = 39,
place = {United States},
year = {Mon Aug 15 00:00:00 EDT 2016},
month = {Mon Aug 15 00:00:00 EDT 2016}
}